NASDAQ:HRMY Harmony Biosciences (HRMY) Stock Forecast, Price & News $34.95 -1.04 (-2.89%) (As of 04:33 PM ET) Add Compare Share Share Today's Range$34.91▼$36.4950-Day Range$30.50▼$36.5952-Week Range$29.81▼$62.08Volume338,001 shsAverage Volume771,622 shsMarket Capitalization$2.10 billionP/E Ratio11.27Dividend YieldN/APrice Target$62.89 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Harmony Biosciences MarketRank™ ForecastAnalyst RatingModerate Buy2.78 Rating ScoreUpside/Downside79.9% Upside$62.89 Price TargetShort InterestBearish23.77% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.35Based on 3 Articles This WeekInsider TradingN/AProj. Earnings Growth40.83%From $2.40 to $3.38 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.3.02 out of 5 starsMedical Sector18th out of 986 stocksPharmaceutical Preparations Industry8th out of 479 stocks 3.4 Analyst's Opinion Consensus RatingHarmony Biosciences has received a consensus rating of Buy. The company's average rating score is 2.78, and is based on 7 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $62.89, Harmony Biosciences has a forecasted upside of 79.9% from its current price of $34.95.Amount of Analyst CoverageHarmony Biosciences has only been the subject of 3 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted23.77% of the float of Harmony Biosciences has been sold short.Short Interest Ratio / Days to CoverHarmony Biosciences has a short interest ratio ("days to cover") of 8.5.Change versus previous monthShort interest in Harmony Biosciences has recently decreased by 2.33%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldHarmony Biosciences does not currently pay a dividend.Dividend GrowthHarmony Biosciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for HRMY. Previous Next 3.0 News and Social Media Coverage News SentimentHarmony Biosciences has a news sentiment score of 1.35. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Harmony Biosciences this week, compared to 4 articles on an average week.Search InterestOnly 6 people have searched for HRMY on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.MarketBeat Follows3 people have added Harmony Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Harmony Biosciences insiders have not sold or bought any company stock.Percentage Held by Insiders28.40% of the stock of Harmony Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions84.76% of the stock of Harmony Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 4.4 Earnings and Valuation Earnings GrowthEarnings for Harmony Biosciences are expected to grow by 40.83% in the coming year, from $2.40 to $3.38 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Harmony Biosciences is 11.27, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 135.97.Price to Earnings Ratio vs. SectorThe P/E ratio of Harmony Biosciences is 11.27, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 89.28.Price to Earnings Growth RatioHarmony Biosciences has a PEG Ratio of 0.53. PEG Ratios below 1 indicate that a company could be undervalued.Price to Book Value per Share RatioHarmony Biosciences has a P/B Ratio of 5.15. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Harmony Biosciences (NASDAQ:HRMY) StockHarmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.Read More Receive HRMY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Harmony Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address HRMY Stock News HeadlinesJune 6, 2023 | finance.yahoo.comHARMONY BIOSCIENCES ANNOUNCES POSITIVE PHASE 2 SIGNAL DETECTION STUDY EVALUATING PITOLISANT FOR EXCESSIVE DAYTIME SLEEPINESS IN PRADER-WILLI SYNDROME AT SLEEP 2023June 5, 2023 | americanbankingnews.comAnalysts Set Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Price Target at $62.89June 9, 2023 | Behind the Markets (Ad)[BREAKING] New "Living Software" to Revolutionize WarfareThis breakthrough will change "the way wars will be fought, and won, for years to come." - Chairman of the Joint Chief of Staff, General Mark Milley Get the name of the company supplying it to the U.S. Army here >>>June 1, 2023 | benzinga.comHarmony Biosciences President Awarded $4.33M Worth of Stock OptionsMay 30, 2023 | finance.yahoo.comHARMONY BIOSCIENCES TO PARTICIPATE IN GOLDMAN SACHS 44th ANNUAL GLOBAL HEALTHCARE CONFERENCEMay 26, 2023 | nasdaq.comOppenheimer Reiterates Harmony Biosciences Holdings (HRMY) Outperform RecommendationMay 24, 2023 | seekingalpha.comHarmony Biosciences: A Company With Solid Fundamentals (Rating Upgrade)May 22, 2023 | markets.businessinsider.comHarmony Biosciences Holdings (HRMY) Gets a Buy from Mizuho SecuritiesJune 9, 2023 | Vantage Point (Ad)Unlock Profit Potential: Find Hidden Trade Opportunities Using A.I.There’s a tool that scans and picks the best stocks…how you approach the trades is up to you. But when you’re forecasting 1 – 3 days in advance, it’s not really a guessing game. Stop guessing and start predicting to add consistency to your trades… no matter what happens in the market. May 12, 2023 | entrepreneur.comTop 3 Biotech Stocks with Breakout PotentialMay 11, 2023 | americanbankingnews.comBrokerages Set Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Price Target at $62.89May 10, 2023 | finance.yahoo.comHARMONY BIOSCIENCES TO PRESENT NEW WAKIX® (PITOLISANT) SAFETY AND EFFICACY DATA AT SLEEP 2023 ANNUAL MEETINGMay 9, 2023 | americanbankingnews.comHarmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Forecasted to Post FY2023 Earnings of $2.36 Per ShareMay 8, 2023 | msn.comHarmony Biosciences Earnings Perspective: Return On Capital EmployedMay 5, 2023 | americanbankingnews.comHarmony Biosciences (NASDAQ:HRMY) PT Raised to $75.00 at Cantor FitzgeraldMay 5, 2023 | americanbankingnews.comHarmony Biosciences (NASDAQ:HRMY) Stock Price Up 8.7% After Analyst UpgradeMay 3, 2023 | seekingalpha.comHarmony Biosciences Non-GAAP EPS of $0.66 beats by $0.10, revenue of $119.13M beats by $2.94MMay 3, 2023 | finance.yahoo.comHarmony Biosciences Holdings First Quarter 2023 Earnings: Beats ExpectationsMay 2, 2023 | finance.yahoo.comHarmony Biosciences (HRMY) Q1 2023 Earnings Call TranscriptMay 2, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Pfizer (PFE) and Harmony Biosciences Holdings (HRMY)May 2, 2023 | finance.yahoo.comHarmony Biosciences Holdings, Inc. (HRMY) Surpasses Q1 Earnings and Revenue EstimatesMay 2, 2023 | seekingalpha.comHarmony Biosciences Holdings, Inc. 2023 Q1 - Results - Earnings Call PresentationMay 2, 2023 | finance.yahoo.comHarmony Biosciences Reports First Quarter 2023 Financial Results and Business UpdatesMay 1, 2023 | benzinga.comEarnings Outlook For Harmony BiosciencesMay 1, 2023 | americanbankingnews.comHarmony Biosciences (HRMY) Scheduled to Post Earnings on TuesdayApril 30, 2023 | americanbankingnews.comFY2023 Earnings Forecast for Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Issued By Cantor FitzgeraldApril 24, 2023 | finance.yahoo.comHARMONY BIOSCIENCES ANNOUNCES JEFFREY M. DAYNO, M.D. APPOINTED PRESIDENT & CHIEF EXECUTIVE OFFICERSee More Headlines HRMY Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart HRMY Company Calendar Last Earnings5/02/2023Today6/09/2023Next Earnings (Estimated)8/01/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:HRMY CUSIPN/A CIK1802665 Webwww.harmonybiosciences.com Phone484-539-9800FaxN/AEmployees180Year FoundedN/APrice Target and Rating Average Stock Price Forecast$62.89 High Stock Price Forecast$75.00 Low Stock Price Forecast$43.00 Forecasted Upside/Downside+75.0%Consensus RatingModerate Buy Rating Score (0-4)2.78 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)$3.10 Trailing P/E Ratio11.59 Forward P/E Ratio14.97 P/E Growth0.53Net Income$181.47 million Net Margins40.19% Pretax Margin25.25% Return on Equity49.67% Return on Assets28.11% Debt Debt-to-Equity Ratio0.42 Current Ratio4.90 Quick Ratio4.85 Sales & Book Value Annual Sales$437.86 million Price / Sales4.92 Cash Flow$3.46 per share Price / Cash Flow10.38 Book Value$6.79 per share Price / Book5.29Miscellaneous Outstanding Shares59,960,000Free Float42,928,000Market Cap$2.15 billion OptionableNot Optionable Beta0.45 Key ExecutivesMr. Jeffrey S. Aronin (Age 55)Founder & Non-Exec. Chairman Comp: $85kMr. John Charles Jacobs M.B.A. (Age 56)Pres, CEO & Director Comp: $885.55kMr. Sandip S. Kapadia CPA (Age 53)M.B.A., Exec. VP & CFO Comp: $717.03kDr. Jeffrey M. Dayno M.D. (Age 66)Exec. VP & Chief Medical Officer Comp: $702.74kMr. Jeffrey Dierks M.B.A. (Age 51)Exec. VP & Chief Commercial Officer Comp: $613.88kMr. Andrew Serafin J.D. (Age 48)M.B.A., Exec. VP & Chief Strategy Officer Comp: $570.92kMr. David BradshawHead of Technical OperationsMs. Sharon GoldbachHead of Facilities Operations & Exec. Admin.Luis SanayHead of Investor RelationsMr. Christian UlrichGen. CounselMore ExecutivesKey CompetitorsHUTCHMEDNASDAQ:HCMAmphastar PharmaceuticalsNASDAQ:AMPHCureVacNASDAQ:CVACVentyx BiosciencesNASDAQ:VTYXMirati TherapeuticsNASDAQ:MRTXView All CompetitorsInsiders & InstitutionsMacquarie Group Ltd.Bought 126,575 shares on 6/1/2023Ownership: 1.382%ProShare Advisors LLCSold 1,116 shares on 5/26/2023Ownership: 0.013%Ameriprise Financial Inc.Sold 54,190 shares on 5/22/2023Ownership: 0.184%Putnam Investments LLCSold 25,965 shares on 5/22/2023Ownership: 0.183%JPMorgan Chase & Co.Sold 38,611 shares on 5/18/2023Ownership: 0.090%View All Insider TransactionsView All Institutional Transactions HRMY Stock - Frequently Asked Questions Should I buy or sell Harmony Biosciences stock right now? 9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Harmony Biosciences in the last year. There are currently 2 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" HRMY shares. View HRMY analyst ratings or view top-rated stocks. What is Harmony Biosciences' stock price forecast for 2023? 9 brokerages have issued twelve-month target prices for Harmony Biosciences' shares. Their HRMY share price forecasts range from $43.00 to $75.00. On average, they expect the company's share price to reach $62.89 in the next year. This suggests a possible upside of 75.0% from the stock's current price. View analysts price targets for HRMY or view top-rated stocks among Wall Street analysts. How have HRMY shares performed in 2023? Harmony Biosciences' stock was trading at $55.10 on January 1st, 2023. Since then, HRMY shares have decreased by 34.8% and is now trading at $35.93. View the best growth stocks for 2023 here. When is Harmony Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 1st 2023. View our HRMY earnings forecast. How were Harmony Biosciences' earnings last quarter? Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) released its earnings results on Tuesday, May, 2nd. The company reported $0.48 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.44 by $0.04. The firm earned $119.13 million during the quarter, compared to analysts' expectations of $118.21 million. Harmony Biosciences had a net margin of 40.19% and a trailing twelve-month return on equity of 49.67%. What ETFs hold Harmony Biosciences' stock? ETFs with the largest weight of Harmony Biosciences (NASDAQ:HRMY) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN), SPDR S&P Pharmaceuticals ETF (XPH), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), Virtus LifeSci Biotech Products ETF (BBP), Invesco S&P SmallCap Health Care ETF (PSCH), Janus Henderson Small/Mid Cap Growth Alpha ETF (JSMD), Invesco S&P SmallCap Quality ETF (XSHQ) and First Trust Nasdaq Pharmaceuticals ETF (FTXH). What other stocks do shareholders of Harmony Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Harmony Biosciences investors own include Advance Auto Parts (AAP), Advanced Micro Devices (AMD), Boeing (BA), Berry Global Group (BERY), Bunge (BG), Carrier Global (CARR), Commercial Metals (CMC), Canadian Solar (CSIQ), Deere & Company (DE) and Eastman Chemical (EMN). When did Harmony Biosciences IPO? (HRMY) raised $101 million in an initial public offering on Wednesday, August 19th 2020. The company issued 4,700,000 shares at a price of $20.00-$23.00 per share. Goldman Sachs, Jefferies and Piper Sandler served as the underwriters for the IPO. What is Harmony Biosciences' stock symbol? Harmony Biosciences trades on the NASDAQ under the ticker symbol "HRMY." Who are Harmony Biosciences' major shareholders? Harmony Biosciences' stock is owned by many different retail and institutional investors. Top institutional investors include FMR LLC (9.33%), BlackRock Inc. (8.27%), State Street Corp (1.74%), Dimensional Fund Advisors LP (1.39%), Macquarie Group Ltd. (1.38%) and Macquarie Group Ltd. (1.38%). Insiders that own company stock include Andreas Wicki, Holdings A/S Novo, Jack Nielsen, Jeffrey Dierks, Jeffrey M Dayno, Jeffrey M Dayno, John C Jacobs and John C Jacobs. View institutional ownership trends. How do I buy shares of Harmony Biosciences? Shares of HRMY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Harmony Biosciences' stock price today? One share of HRMY stock can currently be purchased for approximately $35.93. How much money does Harmony Biosciences make? Harmony Biosciences (NASDAQ:HRMY) has a market capitalization of $2.15 billion and generates $437.86 million in revenue each year. The company earns $181.47 million in net income (profit) each year or $3.10 on an earnings per share basis. How many employees does Harmony Biosciences have? The company employs 180 workers across the globe. How can I contact Harmony Biosciences? Harmony Biosciences' mailing address is 630 W GERMANTOWN PIKE SUITE 215, PLYMOUTH MEETING PA, 19462. The official website for the company is www.harmonybiosciences.com. The company can be reached via phone at 484-539-9800 or via email at lcaperelli@harmonybiosciences.com. This page (NASDAQ:HRMY) was last updated on 6/9/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Harmony Biosciences Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.